RESUMEN
We theoretically investigate the ground states and the spectrum of elementary excitations across the superfluid to droplet crystallization transition of an oblate dipolar Bose-Einstein condensate. We systematically identify regimes where spontaneous rotational symmetry breaking leads to the emergence of a supersolid phase with characteristic collective excitations, such as the Higgs amplitude mode. Furthermore, we study the dynamics across the transition and show how these supersolids can be realized with standard protocols in state-of-the-art experiments.
RESUMEN
We observe signatures of radial and angular roton excitations around a droplet crystallization transition in dipolar Bose-Einstein condensates. In situ measurements are used to characterize the density fluctuations near this transition. The static structure factor is extracted and used to identify the radial and angular roton excitations by their characteristic symmetries. These fluctuations peak as a function of the interaction strength indicating the crystallization transition of the system. We compare our observations to a theoretically calculated excitation spectrum allowing us to connect the crystallization mechanism with the softening of the angular roton modes.
RESUMEN
Longitudinal spin diffusion of two pseudospin domains is studied in a trapped ^{87}Rb sample above quantum degeneracy, and the effect of coherence in the domain wall on the dynamics of the system is investigated. Coherence in a domain wall leads to transverse-spin-mediated longitudinal spin diffusion that is slower than classical predictions, as well as altering the domains' oscillation frequency. The system also shows an instability in the longitudinal spin dynamics as longitudinal and transverse spin components couple, and a conversion of longitudinal spin to transverse spin is observed, resulting in an increase in the total amount of coherence in the system.
Asunto(s)
Enfermedades de los Bovinos/epidemiología , Ciervos , Virus de la Enfermedad Hemorrágica Epizoótica/clasificación , Virus de la Enfermedad Hemorrágica Epizoótica/aislamiento & purificación , Infecciones por Reoviridae/veterinaria , Animales , Secuencia de Bases , Bovinos , Brotes de Enfermedades/veterinaria , Virus de la Enfermedad Hemorrágica Epizoótica/genética , Filogenia , ARN Viral/análisis , Infecciones por Reoviridae/epidemiología , Reunión/epidemiología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/veterinaria , Homología de Secuencia de Ácido Nucleico , Serotipificación/veterinariaRESUMEN
The oral susceptibilities of 17 Culicoides species to infection with African horse sickness virus (AHSV) serotypes 3, 5 and 8 were determined by feeding field-collected midges on AHSV infected horse blood. The mean titres of virus in the bloodmeals for the three serotypes of AHSV were between 5.7 and 6.5 log10 TCID50/ml. Virus was detected, after 10 days incubation at 23.5 degrees C, in the Culicoides imicola Kieffer (Diptera: Ceratopogonidae) that had fed on blood containing AHSV 5 (8.5%) and 8 (26.8%), and in the Culicoides bolitinos Meiswinkel that had fed on AHSV 3 (3.8%), 5 (20.6%) and 8 (1.7%). Although 44.4% of the C. imicola were shown to have ingested AHSV 3 immediately after feeding, no virus was detected in 96 C. imicola after incubation. The relatively high titres of virus recorded in individual midges of both species after 10 days incubation suggested a fully disseminated infection. Previously, C. imicola was considered to be the only field vector of AHSV in Africa. Identifying C. bolitinos as a potential vector for AHSV is an important finding, which if proven will have a significant impact on our understanding of the epidemiology of AHS. No AHSVs could be detected in the other 15 species of Culicoides assayed, which suggests that some of the southern African Culicoides species are refractory to AHSV infection. However, further work with larger numbers of each species will be necessary to confirm this observation.
Asunto(s)
Virus de la Enfermedad Equina Africana , Enfermedad Equina Africana/epidemiología , Ceratopogonidae/virología , Administración Oral , Virus de la Enfermedad Equina Africana/aislamiento & purificación , Animales , Caballos , Serotipificación/veterinaria , Sudáfrica/epidemiologíaRESUMEN
OBJECTIVES: To better define the relationship between platelet count and survival using a retrospective analysis in patients with thrombocytosis and metastatic renal cell carcinoma (RCC), some of whom had a shorter life expectancy than those with a normal platelet count. PATIENTS AND METHODS: The records were reviewed of patients with stage IV RCC who had undergone a variety of adjuvant therapies after nephrectomy between 1972 and 1992. Entry criteria included a tissue diagnosis of RCC, at least one platelet count and a complete follow-up until the time of death. Of 350 patients available for review, 259 met the entry criteria. Patients were divided into two groups: group 1 included 112 patients whose platelet counts remained at < 4 x 105/microL between the time of nephrectomy and the time of death; group 2 included 147 patients with at least one platelet count of > 4 x 105/microL (mean age in each group 57 years). RESULTS: The mean (SD) survival for group 1 was 151 (34) months, compared with 92 (18) months for those in group 2. Using the log-rank chi-square test the difference in survival between the groups was significant (P = 0.005). Controlling for established prognostic indicators of pathological stage, nuclear grade and cell type, using Cox's regression technique, the difference in survival between the groups remained significant (P = 0.015). CONCLUSIONS: These results suggest that patients with metastatic RCC who receive adjuvant therapy and have a persistently normal platelet count have a 64% longer life expectancy than those with thrombocytosis. The difference is highly statistically significant when controlled for nuclear grade, cell type and pathological stage.
Asunto(s)
Carcinoma de Células Renales/mortalidad , Neoplasias Renales/mortalidad , Trombocitosis/mortalidad , Carcinoma de Células Renales/complicaciones , Carcinoma de Células Renales/terapia , Quimioterapia Adyuvante , Humanos , Inmunoterapia/métodos , Neoplasias Renales/complicaciones , Neoplasias Renales/terapia , Nefrectomía/métodos , Recuento de Plaquetas , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Trombocitosis/etiologíaRESUMEN
Rhabdomyosarcoma is a malignant tumor well known to urologists. These tumors arise from the genitourinary system in 20% to 25% of cases, most commonly from the bladder, prostate, vagina, and paratesticular region. This is the first reported case of a rhabdomyosarcoma arising from the ureter. The radiographic findings and ureteroscopic appearance of this tumor suggested a benign fibroepithelial polyp; however, a ureteroscopic biopsy and subsequent nephroureterectomy revealed an embryonal rhabdomyosarcoma.
Asunto(s)
Rabdomiosarcoma , Neoplasias Ureterales , Adulto , Terapia Combinada , Femenino , Humanos , Rabdomiosarcoma/diagnóstico , Rabdomiosarcoma/terapia , Neoplasias Ureterales/diagnóstico , Neoplasias Ureterales/terapiaRESUMEN
OBJECTIVES: To prospectively evaluate a clinical algorithm that predicts nodal status in patients with prostate cancer and to assess the impact on the outcome. METHODS: Between September 1988 and December 1994, 192 patients with organ-confined prostate cancer and considered surgical candidates for radical perineal prostatectomy (RPP) were stratified using the algorithm: prostate-specific antigen (PSA) 20 ng/mL or less, Gleason score 7 or lower, and clinical Stage T2a or lower. Patients failing any of these criteria were placed in the high-risk group and underwent a pelvic lymphadenectomy. Patients who satisfied all the criteria were placed in the low-risk group and underwent RPP without evaluation of the pelvic lymph nodes. Another contemporaneous cohort of patients (n = 65) underwent pelvic lymphadenectomy and radical retropubic prostatectomy (RRP) without use of the algorithm and were used as a control group. Patients were monitored for at least 24 months. RESULTS: In the RPP group, 177 patients were considered low risk according to the algorithm and were not offered staging lymphadenectomy before surgery, whereas 15 patients were categorized as high risk for metastasis and underwent staging lymphadenectomy. In the RRP and lymphadenectomy group, 41 patients were considered at low risk and 24 at high risk of disease spread according to the algorithm. In the RPP group, low-risk patients (no lymphadenectomy) had a PSA recurrence rate (27%) similar to that of low-risk patients in the RRP group with negative lymph nodes (29%), P = 0.8. Similarly, high-risk patients with negative lymph nodes in both groups had a similar recurrence rate (53% for RPP and 50% for RRP). Univariate logistic regression analysis showed that PSA was the most significant predictor for disease recurrence (P = 0.0004) followed by preoperative Gleason scores (P = 0.02) and clinical stages (P = 0.03). Multivariate stepwise analysis demonstrated that Gleason score and clinical stage did not add to the prediction of recurrence over PSA alone. CONCLUSIONS: Staging lymphadenectomy can be omitted in low-risk patients without deleterious effects on the outcome as measured by PSA recurrence.
Asunto(s)
Algoritmos , Escisión del Ganglio Linfático , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Anciano , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios Prospectivos , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangreRESUMEN
OBJECTIVE: To study the clinical signs following bluetongue virus serotypes 1 and 3 infection in Poll Dorset sheep. DESIGN: A clinical and pathological study. PROCEDURE: Twenty Poll Dorset sheep were inoculated with bluetongue virus serotypes 1 or 3, each inoculum having a different passage history. The sheep were examined daily and their clinical appearance and rectal temperatures recorded. Heparinised and non-heparinised blood samples were taken at intervals for virological and serological study. Gross pathological findings were recorded for several sheep at necropsy and tissue samples were collected from three sheep for virological studies. RESULTS: All inoculated sheep developed clinical disease. The clinical signs and gross pathological changes varied considerably but were consistent with damage to the vascular endothelial system. There was a decline in the titres of infectious bluetongue virus and of antigen in tissues collected between 7 and 12 days after infection. CONCLUSIONS: The severity of disease was related to the speed of onset and duration of pyrexia and not the development or titre of viraemia. Generally, those animals with sensitive mouths, depression, coronitis, recumbency and reluctance to move were the most debilitated. Whole blood was the most reliable source of infectious virus from acutely and chronically infected and convalescent animals. However, tissue samples particularly spleen, collected from dead or killed animals suffering from either peracute or acute forms of disease were most appropriate for the rapid confirmation of a clinical diagnosis.
Asunto(s)
Virus de la Lengua Azul/clasificación , Lengua Azul/virología , Viremia/veterinaria , Animales , Anticuerpos Antivirales/biosíntesis , Anticuerpos Antivirales/sangre , Antígenos Virales/análisis , Autopsia/veterinaria , Lengua Azul/inmunología , Lengua Azul/patología , Virus de la Lengua Azul/inmunología , Ensayo de Inmunoadsorción Enzimática/veterinaria , Pase Seriado/veterinaria , Serotipificación/veterinaria , Ovinos , Viremia/inmunología , Viremia/virologíaRESUMEN
Investigations have been carried out to elucidate the possible role of the donkey in the epidemiology of African horse sickness (AHS). These studies have shown that despite the absence of pyrexia or other observable clinical signs, donkeys become infected with virulent AHS virus serotype 4 (AHSV 4) and that they develop a viraemia which can persist for at least 12 days, albeit at a comparatively lower titre than that recorded for similarly infected ponies. AHSV 4 showed a similar tissue tropism in the pony and donkey but the virus appeared to replicate less efficiently in donkey tissues. The only gross pathological changes observed in the donkeys post mortem were increased fluid accumulation in the serosal lined compartments, particularly the peritoneal cavity, and petechial and ecchymotic haemorrhages on the left hepatic ligament. The absence of infectious virus or viral antigens in any of the tissues collected at 14 and 19 days post inoculation (dpi) from 6 experimental donkeys suggest that, though susceptible to infection, the donkey is unlikely to be a long term reservoir for AHSV. Although AHSV 4 was detected in all 6 donkeys following the primary inoculation, no virus could be isolated from blood collected from two donkeys subsequently challenged with a second virulent virus, AHSV 5. Data generated from virus neutralisation tests showed a second primary antibody response, against AHSV 5, in these donkeys at 12 dpi. In contrast, the boost in antibody levels detected from 5 dpi, as measured by ELISA, was probably due to an anamnestic response against the AHSV group-specific viral proteins. Homogenised spleen tissue, collected post mortem from a donkey 7 dpi with AHSV 4, caused a lethal, cardiac form of AHS when inoculated into a susceptible pony.
Asunto(s)
Virus de la Enfermedad Equina Africana/fisiología , Enfermedad Equina Africana/epidemiología , Brotes de Enfermedades/veterinaria , Reservorios de Enfermedades , Equidae , Enfermedad Equina Africana/patología , Enfermedad Equina Africana/virología , Virus de la Enfermedad Equina Africana/inmunología , Animales , Anticuerpos Antivirales/sangre , Antígenos Virales/análisis , Fiebre/epidemiología , Fiebre/veterinaria , Fiebre/virología , Marruecos/epidemiología , Viremia/epidemiología , Viremia/veterinaria , Viremia/virologíaRESUMEN
OBJECTIVE: To evaluate the impact of the camptothecin analogs on human TCC xenograft, both as monotherapy and in combination with cisplatin (CDDP). MATERIALS AND METHODS: Human transitional cell carcinoma (TCC) xenograft tumor line (DU4184) tested by subrenal capsule assay in 112 nude mice(NM-SRCA). CDDP and the camptothecin analogs irinotecan (CPT-11) and 9-aminocamptothecin(9-AC) were evaluated. RESULTS: Both of the camptothecin analogs showed significant short term tumor inhibition which translated into enhanced survival. Maximal tumor inhibition (>95%) was achieved when either of the camptothecin analogs was combined with CDDP with minimal host toxicity. This translated into 400% increase in median survival. While all controls were dead 39 days following tumor implantation, none of the combination treated animals had died. CONCLUSION: The combination of CDDP with these camptothecin analogs is an effective therapy against this model of advanced TCC. These observations suggest potential clinical value.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Camptotecina/análogos & derivados , Cisplatino/uso terapéutico , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Animales , Camptotecina/uso terapéutico , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Irinotecán , Ratones , Ratones Endogámicos BALB C , Estadificación de Neoplasias , Células Tumorales Cultivadas/trasplante , Neoplasias de la Vejiga Urinaria/patologíaRESUMEN
OBJECTIVES: To compare four assays-the Abbott IMx, the Tosoh, the Chiron ACS PSA, and the Chiron ACS PSA2-in their ability to detect prostate-specific antigen (PSA) after radical prostatectomy. METHODS: Serum samples were drawn on all men who had had a previous radical prostatectomy and who were seen in the urology clinic in March 1995. The results of each assay were compared using linear regression. RESULTS: Twenty-two patients had an undetectable PSA by the IMx assay. The PSA was over the residual cancer detection limit (RCDL) of the Tosoh assay in 5 of these patients. The PSA was over the RCDL of the ACS PSA assay in 15 of these patients and over the RCDL of the PSA2 assay in 2 patients. There were no patients whose PSA was less than the RCDL of the ACS PSA assay who had a measurable PSA level by any of the other assays. CONCLUSIONS: There is a difference among PSA assays in their ability to detect low levels of PSA after radical prostatectomy. The ACS PSA assay is the most sensitive, and the IMx assay is the least sensitive.
Asunto(s)
Técnicas para Inmunoenzimas , Recurrencia Local de Neoplasia/sangre , Antígeno Prostático Específico/sangre , Prostatectomía , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/cirugía , Equipos y Suministros , Humanos , Modelos Lineales , Masculino , Valor Predictivo de las PruebasRESUMEN
OBJECTIVES: To determine the incidence of granulomatous prostatitis and acid-fast bacilli (AFB) after intravesical bacillus Calmette-Guerin (BCG) therapy for superficial bladder transitional cell carcinoma (TCC) or carcinoma in situ (CIS). METHODS: One hundred nineteen men underwent radical cystoprostatectomy for invasive bladder cancer from January 1, 1980 through December 31, 1995. Twelve patients had received intravesical BCG therapy before undergoing cystoprostatectomy. Nine men who did not receive intravesical BCG therapy before undergoing cystoprostatectomy served as controls. The surgical specimens were examined with a Ziehl-Neelsen stain for the presence of granulomatous prostatitis and for the presence of AFB. RESULTS: Granulomatous prostatitis was identified in 9 of 12 patients (75%) who had received intravesical BCG therapy. AFB were identified in 7 of 9 patients (77%) with granulomatous prostatitis. CONCLUSIONS: Pathologic evidence of granulomatous prostatitis with AFB is a common occurrence after intravesical BCG therapy and its incidence is far greater than the reported incidence of symptomatic granulomatous prostatitis. AFB discovered during the evaluation of either an increased level of prostate-specific antigen or prostate nodule in otherwise asymptomatic men may require no specific therapy.
Asunto(s)
Adyuvantes Inmunológicos/efectos adversos , Vacuna BCG/efectos adversos , Carcinoma in Situ/terapia , Carcinoma de Células Transicionales/terapia , Granuloma/epidemiología , Granuloma/microbiología , Prostatitis/epidemiología , Prostatitis/microbiología , Neoplasias de la Vejiga Urinaria/terapia , Administración Intravesical , Granuloma/complicaciones , Granuloma/patología , Humanos , Incidencia , Masculino , Prostatitis/complicaciones , Prostatitis/patologíaRESUMEN
BACKGROUND: Luteinizing hormone-releasing hormone agonists (LHRH-a) have become an established treatment for certain patients with prostate carcinoma. LHRH-a are known to decrease bone mineral density. The purpose of this study was to determine the risk of bone fracture in men receiving LHRH-a for prostate carcinoma. METHODS: A retrospective chart review and phone interviews were conducted to determine the incidence of bone fractures occurring in patients receiving LHRH-a for the treatment of prostate carcinoma. Abstracted data included the number of monthly LHRH-a injections, age, clinical stage of disease, sites of metastases, and bone fracture history. RESULTS: Twenty of the 224 patients (9%) treated with LHRH-a for prostate carcinoma between 1988 and 1995 at 3 teaching hospitals had at least 1 bone fracture during treatment with LHRH-a. The duration of treatment to the time of fracture ranged from 1 to 96 months (mean, 22.2 months). Seven fractures (32%) were osteoporotic in nature (i.e., vertebral compression fractures or hip fractures after a fall from standing), whereas 8 fractures (36%) were associated with a significant traumatic event (i.e., a motor vehicle accident, boxing, etc.) and 5 were of mixed etiology. Two of 22 fractures (9%) were pathologic. CONCLUSIONS: This study demonstrated a 9% fracture incidence in a cohort of patients receiving LHRH-a for prostate carcinoma for up to 96 months. The incidence of osteoporotic fractures was 5%.
Asunto(s)
Antineoplásicos Hormonales/uso terapéutico , Fracturas Espontáneas/etiología , Hormona Liberadora de Gonadotropina/agonistas , Osteoporosis/inducido químicamente , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Humanos , Incidencia , Masculino , Registros Médicos , Persona de Mediana Edad , Osteoporosis/complicaciones , Estudios Retrospectivos , Encuestas y Cuestionarios , Factores de TiempoRESUMEN
Low-density lipoprotein (LDL) particles can be separated into subfractions according to size by non-denaturing polyacrylamide gradient gel electrophoresis. Established research methods require specialised equipment and are frequently unsuited to the clinical laboratory. In this study, we utilised a colour flat bed scanner in conjunction with shareware image analysis software to compare LDL particle diameters of isolated LDL with LDL in whole plasma. LDL was isolated by ultracentrifugation and electrophoresed on 3-13% gels (Gradipore; Sydney, Australia) for 2400 Volt-hours in parallel with plasma and molecular size standards. Coomassie Blue-stained gels were scanned in reflexive mode using a colour flat-bed scanner and Adobe Photoshop 3.0 software. Density traces of each lane were obtained using NIH Image software (public domain, USA). LDL particle diameters were determined from calibration curves of the log of molecular diameter of standards against migration distance. There was a good correlation between LDL particle diameters obtained using isolated LDL and whole plasma (r = 0.87, P < 0.001; n = 22). However, the group means (+/- S.D.) (24.7 +/- 0.6 and 24.8 +/- 0.5 nm respectively) were statistically different on the paired t-test (P < 0.05). It is unclear whether this numerically small difference is due to alterations in LDL during the longer preparative procedures for LDL, or to matrix effects during electrophoresis of plasma samples. In conclusion, plasma samples stained with Coomassie Blue and scanned with a colour flat bed scanner can conveniently be used for LDL particle sizing by non-denaturing polyacrylamide gradient gel electrophoresis.
Asunto(s)
Electroforesis en Gel de Poliacrilamida/métodos , Lipoproteínas LDL/sangre , Lipoproteínas LDL/aislamiento & purificación , Adulto , Anciano , Arteriosclerosis/sangre , Arteriosclerosis/etiología , Electroforesis en Gel de Poliacrilamida/instrumentación , Electroforesis en Gel de Poliacrilamida/estadística & datos numéricos , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Fallo Renal Crónico/sangre , Fallo Renal Crónico/complicaciones , Lipoproteínas LDL/química , Masculino , Peso Molecular , Colorantes de Rosanilina , Programas InformáticosRESUMEN
OBJECTIVE: To compare the initial emergency medical services (EMS) prehospital assessment of medical and traumatic cardiopulmonary arrest in the pediatric patient with that of the Office of the Medical Investigator (OMI) and assess differences and implications for EMS training and prevention. DESIGN: Retrospective review of ambulance run forms with the OMI autopsy confirmations. SETTING: An urban EMS system and the state Office of the Medical Investigator. PARTICIPANTS: Patients 15 years of age or less who were treated by prehospital personnel from November 1, 1990, to October 31, 1991, for a medical or traumatic arrest. INTERVENTION: None. MEASUREMENTS AND MAIN RESULTS: Ambulance runs were reported for 2,586 pediatric patients. Of these, 42 (1.6%) had suffered arrests, with 32 (76%) medical arrests and ten (24%) traumatic arrests. Children 1 year of age or less accounted for 75% of the medical arrests, while children more than 1 year of age accounted for 80% of the traumatic arrests (p = 0.003). Overall mortality was 81%. When EMS prehospital assessments of medical and traumatic arrests were compared with autopsy reports, there was good agreement for sudden infant death syndrome (SIDS) (kappa = 0.70), but poor agreement for child abuse (kappa = 0.37). CONCLUSION: The authors found good agreement between EMS prehospital assessments and autopsy diagnoses for identifying pediatric SIDS, but child abuse was not well identified prior to autopsy.
Asunto(s)
Causas de Muerte , Médicos Forenses , Recolección de Datos/normas , Auxiliares de Urgencia , Tratamiento de Urgencia/normas , Paro Cardíaco/diagnóstico , Paro Cardíaco/etiología , Registros Médicos/normas , Adolescente , Distribución por Edad , Niño , Maltrato a los Niños/estadística & datos numéricos , Preescolar , Auxiliares de Urgencia/educación , Femenino , Paro Cardíaco/mortalidad , Paro Cardíaco/prevención & control , Humanos , Lactante , Recién Nacido , Masculino , New Mexico/epidemiología , Estudios Retrospectivos , Muerte Súbita del Lactante/epidemiología , Salud UrbanaRESUMEN
Two open-label, multicenter studies were conducted to evaluate the efficacy and safety of a long-acting depot formulation of leuprolide acetate (22.5 mg) administered intramuscularly every 12 weeks to patients with stage D2 prostate cancer. Clinical evaluations were performed every 12 weeks, and serum testosterone levels were monitored biweekly or weekly for 24 weeks. Onset of castrate levels (< or = 50 ng/dL) of testosterone was achieved within 30 days of the initial depot injection in 87 (95%) of the 92 assessable patients enrolled in the two studies. Mean testosterone levels remained well within the castrate range throughout each dosing interval. Two patients experienced a transient escape (testosterone levels > 50 ng/dL on two consecutive determinations). Delay of an injection of up to 2 weeks did not have an effect on testosterone suppression: in 16 patients in whom the depot injection was delayed by 3 to 14 days, testosterone values remained within the castrate range. A favorable objective tumor response (no progression) to treatment occurred in 85% of the patients. Prostate-specific antigen and prostatic acid phosphatase decreased by 50% or more in 96% and 84% of patients, respectively, with elevated pretreatment values and at least one treatment value. Assessment of local disease status and overall performance status showed improvement or stability in most patients. The most common adverse events were hot flashes (59%), pain (27%), and testicular atrophy (21%). The 22.5-mg depot formulation of leuprolide, which acts in a manner similar to the monthly 7.5-mg depot formulation, was shown to be effective and safe in treating patients with advanced prostate cancer.
Asunto(s)
Leuprolida/administración & dosificación , Neoplasias de la Próstata/tratamiento farmacológico , Preparaciones de Acción Retardada , Humanos , Leuprolida/uso terapéutico , Hormona Luteinizante/sangre , Masculino , Testosterona/sangreRESUMEN
OBJECTIVES: Bropirimine is an orally administered immunostimulant that has been shown to have activity against carcinoma in situ (CIS) of the bladder. To further assess this potential activity, bropirimine was administered to 42 patients for bladder CIS in a Phase II trial. METHODS: Patients were treated with bropirimine 3.0 g/day by mouth for 3 consecutive days each week up to 1 year. Cystoscopy with biopsies and bladder wash cytology were performed quarterly. RESULTS: Twenty (61%) of 33 evaluable patients converted malignant biopsies and bladder wash cytology to negative, including 6 (50%) of 12 who failed prior bacillus Calmette-Guérin (BCG) immunotherapy, 14 (67%) of 21 who had not received prior BCG therapy, and 12 (80%) of 15 with primary CIS. Median response duration exceeds 21 months. Four of the 20 responders did have a papillary tumor recurrence at 3 to 15 months, all Stage Ta or T1. Mild toxicity (grade I or II) suggestive to interferon induction or administration occurred in one third of patients. Headache, transient hepatic enzyme elevations, skin rash, and arthralgias each occurred in 5% to 14% of the patients, with nausea or emesis in 21%. Grade 1 tachycardia/palpitations or chest pain each were noted in 5%. CONCLUSIONS: Oral bropirimine can induce remission of bladder CIS with acceptable toxicity at 3.0 g/day. Bropirimine may be a valuable alternative to cystectomy for some failures of BCG therapy and may have the potential to replace BCG as front-line therapy because of its ease of administration.
Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Carcinoma in Situ/terapia , Citosina/análogos & derivados , Neoplasias de la Vejiga Urinaria/terapia , Adyuvantes Inmunológicos/efectos adversos , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Citosina/administración & dosificación , Citosina/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
The objective of this article is to determine the relationship between microvascular invasion and seminal vesicle invasion in prostatic adenocarcinoma. Radical prostatectomies with seminal vesicle involvement were examined histologically and immunohistochemically with antibodies directed against S-100 protein and factor VIII. Microvascular invasion of the seminal vesicles showed a positive correlation with microvascular and capsular invasion of the prostate (P = 0.006 and 0.048, respectively) and lymph node metastases. Tumor progression was found in 8 of 14 (57%) patients with microvascular invasion of the seminal vesicles, compared with 3 of 22 (14%) without microvascular invasion (P = 0.001). Microvascular invasion of the seminal vesicles is predictive of tumor progression and lymph node metastases in prostatic adenocarcinoma.
Asunto(s)
Adenocarcinoma/patología , Neoplasias de la Próstata/patología , Vesículas Seminales/patología , Adenocarcinoma/irrigación sanguínea , Adenocarcinoma/química , Factor VIII/análisis , Factor VIII/inmunología , Humanos , Inmunohistoquímica , Ganglios Linfáticos/patología , Metástasis Linfática , Masculino , Microcirculación , Invasividad Neoplásica , Próstata/química , Próstata/inervación , Próstata/patología , Prostatectomía , Neoplasias de la Próstata/irrigación sanguínea , Neoplasias de la Próstata/química , Proteínas S100/análisis , Proteínas S100/inmunología , Vesículas Seminales/irrigación sanguínea , Vesículas Seminales/químicaRESUMEN
Polymerase chain reaction (PCR) was used to analyze a rarely deleted region of mitochondrial DNA (mtDNA) from 39 human renal cell carcinomas (RCC) and matched normal kidney tissue removed during radical nephrectomy. One tumor specimen (E.R.) had a unique PCR product approximately 250 base pairs (bp) smaller than the PCR product found in the normal E.R. kidney. Sequence analysis of the tumor-specific PCR fragment revealed a 264 bp deletion in the first subunit (NDI) of NADH:ubiquinone oxidoreductase (complex I) of the electron transport chain. Southern analysis of the RCCs demonstrated that approximately 50% of the mtDNA molecules in the primary RCC contained a unique 3.2 kb EcoRV restriction fragment found only in E.R. tumor mtDNA. Northern analysis demonstrated preferential transcription of the truncated NDI mRNA. None of the five metastases or any normal tissue from E.R. contained levels of the NDI deletion detectable by PCR. This is the first reported case of an intragenic NDI mtDNA deletion.